Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — Technical Presentation (2024)
14 slides from Cg Oncology's technical presentation, 2024
Slide 1: PIVOT-006: A Phase-3, Randomized Study of Adjuvant Intravesical Cretostimogene vs Surveillance
PIVOT-006: A Phase-3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk NMIBC Robert S. Svatek, MD, MSCI - Global Pl, PIVOT-006 UT Health Professor, Department of Urology UT Health, San Antonio San Antonio
Slide 2: What is Cretostimogene Grenadenorepvec?
What is Cretostimogene Grenadenorepvec? o o o o GM-CSF- Granulocyte-macrophage colony-stimulating factor; Rb- Retinoblastoma
Slide 3: Oncolytic Immunotherapy: Selective Oncolysis and Potent Anti-Tumor Immune Response
Oncolytic Immunotherapy: Selective Oncolysis and Potent Anti-Tumor Immune Response Enters target cell Replicates and kills the cell
Slide 4: Significant Unmet Need with High Prevalence of Intermediate-Risk NMIBC in the U.S.
Significant Unmet Need with High Prevalence of Intermediate-Risk NMIBC in the U.S. • • • • • •
Slide 5: NCCN Guidelines: Management per NMIBC Risk Group
National Cee Cancer Comprehensive NCCN Guidelines Version 3.2024 Non-Muscle Invasive Bladder Cancer NCCN Guidelines Index Table of Contents Network® Discussion MANAGEMENT PER NMIBC RISK GROUP AUA RISK INITIAL MANAGEMENT FOLLOW-UP GROUP SEE BL-2) Low 1° ——_—_—_—_—____—__» i P.a |- Cytology positive (
Slide 6: Intermediate-Risk NMIBC Study Design Considerations
Intermediate-Risk NMIBC Study Design Considerations • • • • • •
Slide 7: Contieri R., et al. Eur Urol Suppl 2024
Contieri R., et al. Eur Urol Suppl 2024;85 (S1): S1717
Slide 8: Phase 3 Adjuvant Cretostimogene vs Surveillance for Intermediate-Risk NMIBC
Phase 3 Adjuvant Cretostimogene vs Surveillance for Intermediate-Risk NMIBC • • • • • • • •
Slide 9: Exclusion Criteria
Exclusion Criteria • o o o o o o o • o • •
Slide 10: Efficacy Assessments
Efficacy Assessments o o ▪ o ▪ ▪ o o
Slide 11: Experience with Cretostimogene
Experience with Cretostimogene • • • •
Slide 12: SUO-CTC Trial: PIVOT-006 Phase-3 Adjuvant Cretostimogene vs Surveillance in IR-NMIBC
SUO-CTC Trial: PIVOT-006 Phase-3 Adjuvant Cretostimogene vs Surveillance in IR-NMIBC • • • • • •
Slide 13: Acknowledgements
Acknowledgements Pivot-o08 All Bladder Cancer Patients and Their Families The Study Coordinators and Nurses CTC Key Collaborators CG Oncology Trinity Bivalacqua, Univ of Penn, PA Shelly Basye Kara Sabourin Neal Shore, CURC, SC Andy Darilek John McAdory Gautam Jayram, Urology Associates, TN —_ Natali
Slide 14: Questions?
QUESTIONS? satis i] UT Health San Antonio